Preparation and characterization of solid lipid nanoparticles containing silibinin

Drug Delivery

Volumn 14, Issue 6, 2007, Pages 381-387

  Zhang, J Q ^a,b   Liu, J ^c   Li, X L ^b   Jasti, B R ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c Academy of Taiji Medical Sciences   (China)

Author keywords

Colloidal Carriers; DSC; Silibinin; Solid Lipid Nanospheres

Indexed keywords

POLYOXYETHYLENE STEARYL ETHER; SILIBININ; SOLID LIPID NANOPARTICLE; STEARIC ACID;

ARTICLE; CHEMICAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; PARTICLE SIZE; PRIORITY JOURNAL; THERMAL ANALYSIS; ZETA POTENTIAL;

ANTIOXIDANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SILYMARIN; STEARIC ACIDS; SURFACE-ACTIVE AGENTS;

EID: 34547957453     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540701203034     Document Type: Article

References (27)

1. Bocca, C., Caputo, O., Cavalli, R., Gabriel L., Miglietta A., and Gasco M. R. 1998. Phagocytic uptake of fluorescent stealth and non- stealth solid lipid nanoparticles. Int. J. Pharm. 175:185-193.
2. Cavalli, R., Bocca, C., Miglietta A, et al. 1999. Albumin adsorption on stealth and non- stealth solid lipid nanoparticles. S.P. Pharm. Sci. 9:183-189.
3. Dubes, A., Lopez, H. P., Abdelwahed, W., Degobert, G., Fessi, H., Shahgaldian, P., and Coleman, A.W. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur. J. Pharm. Biopharm. 55:279-282.
4. Flora, K., Hahn, M., Rosen, H., et al. 1998. Milk thistle (silybum marainum) for the therapy of liver diseases. Am. J. Gastroenterol. 93:139.
5. Gert, S., Sheila, D. B., Toos, D., and Danilo D. L. 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Del. Rev. 17:31-48.
6. Gref, R., Domb, A., Quellec, P., Blunk, T., Muller, R. H., Verbavatz, J. M., and Langer, R. 1995. The he controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug. Del. Rev. 16:215-233.
7. Gref, R., Minimatake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., and Langer, R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1604.
8. Illum, L., Davis, S. S., Wilson, C. G., Thomas, N. W., Frier, M., and Hardy, J. G. 1982. Blood clearance and organ deposition of intravenously administered colloidal particles- the effect of particle size, nature and shape. Int. J. Pharm. 12:135-146.
9. Illum, L., Davis, S. S., Muller, R. H., Mak, E., and West, P. 1987. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer poloxamine 908. Life Sci. 40:367-370.
10. Koppel, D. E. 1972. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: the method of cumulants. J. Chem. Phys. 57:4814-4816.
11. Miguez, M. P., Anundi, I., Sainz-Pardo L. A., et al. 1994. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem. Biol. Interact. 91:51.
12. Moghimi, S. H., Hawley, A. E., Christy, N. M., Gray, T., Illum, L., and Davis, S. S. 1994. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the lymph nodes. FEBS Letters. 344:25-30.
13. Moghimi, S. M. 1995. Mechanism regulating body distribution of nanospheres conditioned with pluronic and tetronic block copolymers. Adv. Drug. Del. Rev. 16:183-193.
14. Muhlen, A., Schwarz, C., and Mehnert, W. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm Biopharm, 45:149-155.
15. Muller, R. H. 1991. Colloidal Carriers for Controlled Drug Delivery and Targeting. Boca Raton, Fl: CRC Press.
16. Muller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., Muhlen, A., Weyhers, H., Freitas, C., and Ruhl, D. 1995. Solid lipid nanoparticles (SLN) - an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41:62-69.
17. Muller, R. H., Mader, K., and Gohla, S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50:161-177.
18. Roberta, C., Otto, C., and Maria, R.G. 2000. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 10: 305-309.
19. Saller, R., Meirer, R., and Brignoli, R. 2001. The use of silymarin in the treatment of liver diseases. Drugs 612: 2035.
20. Shahgaldian, P., Silva, E. D., Coleman, A. W., Rather, B, and Zaworotko, M. J. 2003. Para-acyl-calyx-arene based solid lipid nanoparticles (SLN): a detailed study of preparation and stability parameters. Int. J. Pharm. 253:23-38.
21. Siekmann, B., and Westesen, K. 1996. Investigations on solid lipid nanoparticles prepared by precdipitation in o/w emulsions. Eur. J. Pharm. Biopharm. 43:104-109.
22. Sjostrom, B., and Bergenstahl, B. 1992. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions. 1 Model studies of the precipitation of cholesteryl acetate. Int. J. Pharm. 88:53-62.
23. Sjostrom, B., Kaplun, A., Talmon, Y., and Cabane, B. 1995. Preparation and structure of a water- in- oil cream containing lipid nanoparticles. Pharm Res. 1:39-48.
24. Sonia, A., Aman, T., and Katare, O. P. 2004. Formulation, characterization and in vitro evaluation of silymarin- loaded lipid microspheres. Drug Del. 11:185-191.
25. Souto, E. B., Wissing, S. A., Barbosa, C. M., and Muller, R. H. 2004. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 278:71-77.
26. Troster, S. D., Muller, U., and Kreuter, D. 1990. Modification of the body distribution of poly (methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61:85-100.
27. Wellington, K., and Jarvis, B. 2001. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio. Drugs 15:465.